A Randomized, Double-Blind, Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of FLX-787-ODT for Treatment of Muscle Cramps in Adult Subjects With Charcot-Marie-Tooth Disease
Phase of Trial: Phase II
Latest Information Update: 02 Dec 2017
At a glance
- Drugs FLX 787 (Primary)
- Indications Charcot-Marie-Tooth disease; Cramp
- Focus Therapeutic Use
- Acronyms COMMIT
- Sponsors Flex Pharma
- 06 Nov 2017 According to a Flex Pharma media release, the company expects to report topline results from this trial in the third quarter of 2018.
- 16 Oct 2017 Status changed from not yet recruiting to recruiting, according to a Flex Pharma media release.
- 11 Oct 2017 Planned initiation date changed from 1 Aug 2017 to 1 Oct 2017.